Kornimate/medical-research-clean huggingface dataset:
ozurdex in reducing pvr after vitreotomy in pdr

Conditions: Diabetic Retinopathy

Summary: diabetic retinopathy is a significant source of visual morbidity in the adult population. complications of diabetic retinopathy include ischemic maculopathy, macular edema, and sequelae of fibrovascular proliferation, such as vitreous hemorrhage (vh), tractional retinal detachment (trd), and neovascular glaucoma.pars plana vitrectomy (ppv) is traditionally performed for nonclearing vh, significant fibrovascular proliferation, refractive macular edema, and/or trd, particularly if macula-involving. however, the pathogenesis is complex and multifactorial: pro-infammatory cytokines and chemokines signifcantly contribute to the disease development and promote ischemic changes in the retina. therefore, there is a potential role for intravitreal steroids in disease modifcation.

diabetic retinopathy is a significant source of visual morbidity in the adult population. complications of diabetic retinopathy include ischemic maculopathy, macular edema, and sequelae of fibrovascular proliferation, such as vitreous hemorrhage (vh), tractional retinal detachment (trd), and neovascular glaucoma.pars plana vitrectomy (ppv) is traditionally performed for nonclearing vh, significant fibrovascular proliferation, refractive macular edema, and/or trd, particularly if macula-involving. however, the pathogenesis is complex and multifactorial: pro-infammatory cytokines and chemokines signifcantly contribute to the disease development and promote ischemic changes in the retina. therefore, there is a potential role for intravitreal steroids in disease modifcation. corticosteroids reduce not only leukostasis and infammatory cytokine production, but also vegf expression. experimentally, corticosteroids potentially can influence both the inflammatory and the proliferative components of the pvr process via a variety of modes of administration without evidence of demonstrable retinal toxicity. so, this study is carried out for the purpose of investigating the efficacy of slow-release dexamethasone implant in proliferative vitreoretinopathy of postoperative proliferative diabetic retinopathy.

Eligibility criteria:
inclusion criteria: * macula off treatment naive trd second to pdr causing visual loss; * treated by standardize ppv, endolaser and silicone oil tamponade with or without dex implant at the end of the surgery within 12 months from diagnosis of trd; * hba1c is less than 10% with type 1 or 2 diabetes mellitus exclusion criteria: * other concomitant ocular diseases that cause rd ( for example rhegmatogenous retinal detachment, exudative retinal detachment, other causes for trd); * any previous injection of dex implant; * abnormalities of the vitreoretinal interface, such as epiretinal membrane, vitreomacular traction without rd

Keywords: pdr; pvr; ozurdex
x-ray dose reduction study for cardiac angiography and intervention

Conditions: Vascular Diseases

Summary: clarityiq is a novel x-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. this is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. furthermore, smaller focal spot sizes and shorter pulses are used, which are known to positively influence image quality . the final effect on the clinical image quality is investigated in this study.

fluoroscopically guided procedures are associated with a risk of radiation injury to the skin, caused by high peak skin dose. the increasingly complex nature of many of the interventions performed requires the use of significant amounts of radiation for their completion. of particular relevance to dose reduction concerns are obese patients, for whom additional radiation is often necessary to obtained sufficient diagnostic quality, as well as patients suffering from chronic total coronary occlusions (cto), for whom long procedures with extended radiation time and contrast usage are common. in order to introduce a dose reduction technology the most important aspect is to validate the diagnostic image information. philips has developed a new algorithm that is capable to process images with similar image quality but acquired at lower dose.

Eligibility criteria:
inclusion criteria: * patients older than 18 years of age undergoing coronary angiography exclusion criteria: * patients not willing or unable to give consent to participate * patients already involved in a clinical trial * patients under the age of 18 * pregnant women and breastfeeding women * patients with severe kidney disease (egfr \< 60)

Keywords: x-rays image processing cardiovascular procedure
placement of peripheral venous catheters under echo guidance in a post-emergency medical service

Conditions: Catheterization, Peripheral; Echography; Hospital Units

Summary: compare the number of attempts to place a peripheral venous catheter in the group of patients hospitalized in the post-emergency unit and benefiting from echo guidance and therapeutic communication, to the group of patients hospitalized on the post-emergency unit using traditional technique.


Eligibility criteria:
inclusion criteria: * hospitalized in the post-emergency unit * requiring the placement of a venous catheter in the post-emergency unit * affiliation to social security or benefiting from such a scheme * informed and written consent signed exclusion criteria: * protected person (art. l1121-5 to l1121-8 of the csp) * patient included in another interventional study * patient already included for a first catheter placement in the post-emergency unit.
outcome of zeiss at lara edof lens implantation in vitrectomized eyes

Conditions: Vitreous Disorder; Cataract

Summary: to determine the surgical outcome and patient satisfaction in patients who underwent at lara lens implantation during or after vitrectomy at a relatively young age (around 55 years of age), mostly to treat (urgent) retinal detachment.

the surgical outcome is defined as the patient satisfaction determined by patient questionnaires. * visual quality: catquest questionnaire * near vision: navs questionnaire * glare: apples questionnaire these questionnaires are standardized and validated, although no cut-off values have been determined. hence, the results drawn from these questionnaires are descriptive only.

Eligibility criteria:
inclusion criteria: * patients that had a lara iol implanted in combination with vitrectomy. * patients that had a lara iol implanted in during surgery for cataract secondary to vitrectomy. exclusion criteria: * patients with a lara iol implanted without concomitant or earlier vitrectomy

Keywords: lara edof lens intra ocular lensimplantation cataract vitrectomy
phase ii investigation of 99mtc-rbitistatin for imaging venous thrombosis

Conditions: Venous Thrombosis

Summary: 99mtc-rbitistatin is a radiolabeled polypeptide which is designed to stick to blood clots so that the blood clots can be detected by imaging. the purpose of this trial is to evaluate in patients the safety of 99mtc-rbitistatin and its ability to locate blood clots in the arms and legs.


Eligibility criteria:
inclusion criteria: * peripheral acute venous thrombosis diagnosed by vascular ultrasound * is able to give informed consent * is likely to complete the study exclusion criteria: * is pregnant * is lactating * has a history of prior severe allergic reactions (anaphylactic response) * prior use of gp iib/iiia antagonist (e.g., abciximab, eptifibatide) * has a platelet count \<100,000 or history of thrombocytopenia * has a history of stroke * has a history of recent bleeding documented by decreasing hemoglobin (\>1 gm) in last 7 days
mexidol® in the rehabilitation treatment of patients with acute cerebral failure

Conditions: Ischemic Stroke, Acute

Summary: the use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure

modern neurorehabilitation is a set of basic and adjuvant treatment methods that provide a modulating effect on the neurorestoration process. the range of basic rehabilitation practices includes kinesiotherapy, occupational therapy, speech therapy, and neuropsychology. adjuvant methods include physiotherapeutic and medicinal methods. for this study, the investigators chose mexidol® as an adjuvant metabolic medicine, which has the ability to modulate receptor complexes of brain membranes, in particular benzodiazepine, gaba, acetylcholine, enhancing their ability to bind to specific ligands. this pharmacodynamic feature of the drug can have a positive effect on the psycho-emotional state of patients, which in turn will increase motivation and, consequently, the success of the rehabilitation process

Eligibility criteria:
inclusion criteria: * acute ischemic stroke * montreal cognitive assessment (moca) test \>15; ≤22 exclusion criteria: * under 18 years old * epilepsy * pregnancy * acute failure of one or more organ systems * purulent-inflammatory disease of any localization * participating in any other clinical trial

Keywords: ischemic stroke acute stroke cerebral stroke traumatic brain injury acute cerebrovascular accident acva acute cerebral failure neuroprotection mexidol ethylmethylhydroxypyridine succinate
safety study of a long-acting injectable steroid to treat knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: the main purpose of this study is to understand the pharmacokinetics of ep-104iar and to determine whether it is safe to use in patients with osteoarthritis (oa) of the knee. the study will also provide some preliminary insights into whether the experimental treatment reduces pain in the knee. osteoarthritis is the most common joint disease, affecting over 20 million people in the us alone. currently, pain treatments that are injected directly into the knee often work for only a short time and may also have side effects within the rest of the body. the experimental treatment is a steroid that is in the same family of drugs as the most common current injectable treatments for knee osteoarthritis. for this study, the drug is coated with a polymer intended to prolong the time it stays inside the knee and lessen potential side effects.


Eligibility criteria:
inclusion criteria: * oa of index knee * kellgren lawrence grade 2 or 3 * patient-reported pain (ptpain) of index knee ≥4 but ≤9 * ptpain of non-index knee \<6 * bmi ≦ 40 kg/m2 exclusion criteria: * intra-articular joint injection in the index knee within the past 8 weeks for glucocorticoids and 6 months for hyaluronic acid * insulin-dependent diabetes * active infection * pregnant or breast feeding

Keywords: osteoarthritis knee
left ventricular stiffness vs. fibrosis quantification by t1 mapping in heart failure with preserved ejection fraction

Conditions: Heart Failure With Normal Ejection Fraction

Summary: stiffmap-hfpef trial is an investigator initiated, observational, single-center study that will evaluate whether fibrosis quantification by cardiac mri correlates with left and right ventricular stiffness derived from pressure-volume analysis, aiming to clarify if cardiac mri is a valid, non-invasive method to assess diastolic function in patients with heart failure with preserved ejection fraction.

heart failure with preserved ejection fraction (hfpef) and diastolic dysfunction is a growing medical challenge. to date almost every second patient with heart failure has a preserved ejection fraction and recent data show that outcomes in these patients are as bad as in those with reduced ejection fraction. in clinical routine the diagnosis of hfpef is complicated by indirect assessment of diastolic function. mechanistically the diastolic dysfunction is among others believed to be caused by the development of diffuse myocardial fibrosis with an increase of extracellular matrix. direct assessment of the intrinsic diastolic function and stiffness of the ventricle can be obtained by pressure-volume-curve tracings through a conductance catheter. although this offers the benefit of assessing load-dependent and load-independent parameters of diastolic function as well as information on contractility and ventricular-arterial coupling, the use of this technique is limited by its invasiveness in daily care. newer mri techniques have made it possible to quantify not only local fibrosis but also diffuse fibrosis (i.e. t1-mapping) and determine extracellular volumes. moreover, the role of right ventricular function is in hfpef is not well defined. aim of the current study is therefore to evaluate the role of mri in assessing cardiac fibrosis in the context of impaired lv diastolic function in hfpef patients, as well as to evaluate the role of systolic and diastolic right ventricular functional impairment in this patient cohort.

Eligibility criteria:
inclusion criteria: * lv-ef \> 50% * indication for invasive cardiac catheterization exclusion criteria: * know cad or cad in angiography (stenoses \> 50%) * acute coronary syndromes * cerebral ischemia within the last year * contraindications for mri * more than mild valvular disease * constrictive pericarditis, restrictive cardiomyopathy, pericardial effusion * pregnancy * enrolment in other study
alcohol biomarkers in post-liver transplant patients

Conditions: Alcohol-related Liver Disease

Summary: the aim of this study is to compare the predictive validity and reliability of peth testing at detecting alcohol use in post liver transplant patients. a prospective cohort study will be used to test the primary hypothesis. subjects enrolled in the study will be followed for 12 months with biomarker levels drawn at baseline, six and 12 months. the baseline interview will inquire about the previous 30 day alcohol and tobacco use; lifetime and 12 month diagnostic and statistical manual-iv criteria for alcohol abuse and/or dependence; prior alcohol treatment; history of abstinence prior to transplant; co-morbid medical issues; and depression. the six and 12 months interview will focus on previous 30 day alcohol use. the baseline, six and 12 months interviews will be conducted face-to-face at each site. while many patients who receive a transplant do not live near the academic medical center that performed the surgery patient, they normally have a transplant clinic visit 1-2 times per year. medical records and transplant databases will be assessed to assess the other variables of interest.

patients who have a positive peth will be asked to have a confirmatory test performed 10-14 days after a positive result (peth \>20ng/ml). the rationale for this procedure is to determine the test retest reliability of this marker and as well as being able to correlate levels of drinking with changes in biomarker levels over time. there is limited information on the length of time peth levels remain elevated in transplant patients after drinking episodes. hypothesis h.1. peth will have a significantly higher "area under the receiver operating characteristic (roc) curve" in a sample of post-transplant patients who report any alcohol use in the past 30 days compared to the control group. h.2. peth will have a significantly higher "area under the roc curve" in a sample of post-transplant patients who report daily alcohol use of \>40 grams/day (three drinks/day) in the past 30 days compared to the control group. h.3. peth will have a significantly higher "area under the roc curve" in a sample of post-transplant patients who report heavy episodic drinking (\>60 grams of alcohol, eight or more occasions in the past 30 days) compared to the control group. h.4. peth levels will be \<20 ng/ml in the control sample of 50 post transplant patients who do not have a history of alcohol dependence or alcohol related liver disease. h.5. the test-retest reliability of peth will be \>0.90.

Eligibility criteria:
inclusion criteria: * men and women 18 years and over * participant must have received a liver transplant after january 1, 2003 * participant must be six months or more post-transplant * mini-mental status score of greater than or equal to 20 * participant must be well enough to participate in the research procedures over a 12 month period * participant must continue to be followed by the transplant center exclusion criteria: * individuals who do not consent
a sardine diet intervention study to assess benefits to the metabolic profile in type 2 diabetes mellitus patients

Conditions: Type 2 Diabetes

Summary: work hypothesis a diet rich in sardine will improve the metabolic control in type 2 diabetes patients.


Eligibility criteria:
inclusion criteria: * age \> 40 years and \< 85 * bmi ≥ 25 and \< 35 * patients diagnosed with type 2 diabetes at onset or treated only by diet * hba1c between 6.0 and 8.0% (based on the last measured and documented laboratory measurement of the previous 3 months) * usual consumption ≤ 3 fish per week exclusion criteria: * t2d treated with antidiabetic oral drugs and/or insulin * current or previous (within 3 months) intake of omega 3 suplements * known allergy or intolerance to fish or fish protein * diagnosis of active neoplasic disease * suffering from an acute illness which requires a recovery period higher than one week * currently chronic treatment with oral steroids or nonesteroidal anti-inflammatory for more than 5 days, at least 1 month before randomization * pregnant or breast-feeding patients * serious acute vascular events (cardiac or cerebral) diagnosed previous 2 months before the randomization * current or previous (within 6 months) participation in another study * chronic renal insufficiency (creatinine \>1,5 mg/dl) * any conditions that the investigator considers may render the patient unable to complete the study during the interventional study, based on current standards of t2d care, doctors will introduce anti-diabetic oral drugs or insulin into the patient's treatment, where they consider it to be necessary.

Keywords: diet sardine type 2 diabetes
the effect of remote ischemic conditioning on the microcirculation in sepsis

Conditions: Septic Shock; Sepsis

Summary: this study is an evaluation of the effect of remote ischemic conditioning on sublingual microcirculation in patients with sepsis.

this prospective open-label trial is performed in mixed icu in a tertiary teaching hospital. investigators include patients with sepsis or septic shock within the first 24 h after icu admission. remote ischemic conditioning (ric) procedure comprise three repetitions of brachial cuff inflation to 200 mmhg for five minutes following deflation to 0 mmhg for another five minutes. the procedure overall took 30 minutes. ric is performed at inclusion and repeated 12 h and 24 h later. sublingual microcirculatory measurements are obtained before and after each ric procedure, using incidence dark field (idf) device.

Eligibility criteria:
inclusion criteria: * patients with sepsis or septic shock within the first 24 h after icu admission. exclusion criteria: * age \< 18 years, * pregnancy, * advanced malignancy, * peripheral artery disease affecting both arms, * oral mucosal inflammation or injury or technical difficulties in obtaining sublingual images.

Keywords: microcirculation remote ischemic conditioning sepsis
comparative analysis of the efficacies in neoadjuvant chemotherapy of breast cancer

Conditions: Breast Neoplasms

Summary: the purpose of this study is to compare the short-term and long-term efficacies and the safeties of pirarubicin plus docetaxel(at group) and pirarubicin plus cyclophosphamide followed by docetaxel(ac-t group) in neoadjuvant chemotherapy of breast cancer.

based on the results of nsabp(national surgical adjuvant breast and bowel project) b27 trial, anthracyclines(a) and taxanes(t) are most commonly recommended in neoadjuvant chemotherapy of breast cancer. pirarubicin is one of anthracyclines and by embedding the dna double stranded, which inhibits dna replication and rna synthesis, thereby impedes the rapid growth of cancer cells. docetaxel in one of taxanes and by strengthening the tubulin polymerization, inhibiting of microtubule depolymerization and leading to the formation of stable non functional microtubule bundles, which destroys mitosis of tumor cells.

Eligibility criteria:
inclusion criteria: * histopathologically diagnosed with stage i-iii breast cancers; * clearly confirmed er, pr and her2 statuses; * the state of axillary lymph nodes was determined through the relevant examination steps (puncture or sentinel lymph node biopsy); * the patients were not treated with neoadjuvant therapy and surgery. exclusion criteria: * the patients whose breasts or axillary lumps had received excision biopsy; * the patients who had severely abnormal organ functions or who could not tolerate chemotherapy, * the patients with severe concomitant diseases; * the patients with heart disease or left ventricular ejection fraction (lvef) \<50%.

Keywords: breast tumor neoadjuvant chemotherapy pathological complete remission
investigation on medical management of dry eye patients

Conditions: Dry Eye Syndrome

Summary: dry eye is a common complaint in patients encountered by ophthalmologists, which may result from the inflammatory response and can occur in the absence of systemic disease. however, the management of dry eye syndrome in real setting warrants assessment but remains lacking in taiwan. we conducted an perspective observational study to evaluate the medical management of dry eye patients.


Eligibility criteria:
inclusion criteria: * have given a written informed consent * clinical diagnosis of dry eye syndrome * have at least one schirmer's test positive result (less than 10mm/5min) in at least one eye within one year exclusion criteria: * pregnancy * cognitive or psychiatric deficit that precludes informed consent * cognitive or psychiatric deficit that precludes ability to perform requirements of the investigation

Keywords: dry eye syndrome
tbtc study 25: study of the tolerability of higher doses of rifapentine in the treatment of tuberculosis

Conditions: Tuberculosis

Summary: randomized, double-blind study of the tolerability of three different doses of rifapentine

prospective, randomized, double-blinded, comparative study. patients are randomized at the completion of induction phase therapy. sample-size is 50 hiv-seronegative patients with culture-positive, drug susceptible tb in each treatment arm. the first 75 patients will be randomized 2:1 to 900 mg:600 mg rifapentine. the second 75 patients will be randomized 2:1 to 1200 mg:600 mg rifapentine. the dsmb will review tolerability and safety data on the first 21 patients enrolled (at the 900 mg and 600 mg doses) and approve proceeding to enrollment at the 1200 mg dose.

Eligibility criteria:
inclusions: 1. drug susceptible culture-positive tuberculosis 2. adequate induction therapy 3. age \>18 4. normal screening labs 5. karnofsky \>=60 6. informed consent 7. birth control if of child bearing potential exclusions: 1. silicotb 2. skeletal or cns tb 3. pregnant or breastfeeding 4. intolerance to inh or rifamycins 5. over 70 days tb treatment just prior to enrollment

Keywords: tuberculosis tb rifapentine safety dose